Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
3.81
-0.12 (-3.05%)
At close: May 02, 2025, 3:59 PM
3.81
-0.15%
After-hours: May 02, 2025, 05:45 PM EDT
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers.
The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc.
| Country | United States |
| IPO Date | Jul 17, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | David A. Happel |
Contact Details
Address: 155 Bovet Road San Mateo, California United States | |
| Website | https://sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President & Director |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development |
| Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer |
| Robert D'Urso | Senior Vice President of New Products |
| Urs Greber Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Filing |
| Mar 12, 2025 | S-8 | Filing |
| Mar 12, 2025 | S-8 | Filing |
| Mar 12, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | 8-K | Current Report |